ArticlePloS one2020
Preclinical approaches in vulvovaginal candidiasis treatment with mucoadhesive thermoresponsive systems containing propolis.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Antifungal activity of propolis against Candida spp.New microbes and new infections · 2026Review
- Advanced Propolis Delivery: Strategies for Improved Bioavailability and Therapeutic Efficacy.ACS omega · 2026Review
- Anatomopathological uterine findings ofJournal of medical microbiology · 2026Article
- Integrative Therapies in Wound Healing in Small Animals: An Approach Beyond Traditional Medicine.Veterinary sciences · 2026Review
- Understanding the Effect of Propolis and Its Derivatives AgainstJournal of fungi (Basel, Switzerland) · 2026Review
- Therapeutic Potential of Propolis in Preclinical Models of Cancer and Infectious Diseases: A Review.International journal of molecular sciences · 2025Review
- Chemical Composition, Biocompatibility, and Anti-Pathogens (Basel, Switzerland) · 2025Article
- Candida albicans migrates itself from the vagina to the uterus and ovaries in estrogenized mice.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Antimicrobial Properties of Hive Products and Their Potential Applications in Human and Veterinary Medicine.Antibiotics (Basel, Switzerland) · 2025Review
- Bee-Inspired Healing: Apitherapy in Veterinary Medicine for Maintenance and Improvement Animal Health and Well-Being.Pharmaceuticals (Basel, Switzerland) · 2024Review
- From plants to particles: herbal solutions and nanotechnology combating resistant vulvovaginal candidiasis.Therapeutic delivery · 2024Review
- Biological Activity and Chemical Composition of Propolis Extracts with Potential Use in Vulvovaginal Candidiasis Management.International journal of molecular sciences · 2024Article
- Performance of Two Extracts Derived from Propolis on Mature Biofilm Produced byAntibiotics (Basel, Switzerland) · 2022Article
- A New Approach for the Treatment of Recurrent Vulvovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo.Journal of fungi (Basel, Switzerland) · 2022Article
- Perspectives for Uses of Propolis in Therapy against Infectious Diseases.Molecules (Basel, Switzerland) · 2022Review
- Antifungal Properties of Chemically Defined Propolis from Various Geographical Regions.Microorganisms · 2022Review
- Research Progress on Therapeutic Effect and Mechanism of Propolis on Wound Healing.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Antiviral, Antibacterial, Antifungal, and Antiparasitic Properties of Propolis: A Review.Foods (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) is a common vaginitis that affects women, especially in childbearing age, caused by Candida albicans in almost 80% of cases. Considering the limited drug arsenal available and the increasing fungal resistance profile, the search for new therapeutic sources with low toxicity and easy administration should be supported. Propolis has been used as a traditional medicine for multiple diseases, considering its particular composition and pharmaceutical properties that permits its wide applicability; it has also emerged as a potential antifungal agent. Thus, this study performed an in vitro and in vivo investigation into the efficacy of a new mucoadhesive thermoresponsive platform for propolis delivery (MTS-PRPe) in a preclinical murine model of VVC treatment caused by C. albicans. The methodologies involved chemical analysis, an assessment of the rheological and mucoadhesive properties of propolis formulations, in vitro and in vivo antifungal evaluations, histological evaluations and electron microscopy of the vaginal mucosa. The results demonstrated the antifungal activity of propolis extract and MTS-PRP against the standard strain and a fluconazole-resistant clinical isolate of C. albicans, in both in vitro and in vivo assays. These results were similar and even better, depending on the propolis concentration, when compared to nystatin. Thus, the formulation containing propolis exhibited good performance against C. albicans in a vulvovaginal candidiasis experimental model, representing a promising opportunity for the treatment of this infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.